Keyword: CMS

Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.

The Trump administration's proposal to lower Medicare Part B drug prices has been met with plenty of pushback—and it's not just coming from pharma.

Pfizer, Eli Lilly, Sanofi and Johnson & Johnson chimed in on the federal government’s plan to tag pharma TV ads with drug prices.

Lawmakers on both sides of the aisle refuse to let go of the proposal to force drug pricing into consumer advertising, but they're not the only ones.

As the federal comment deadline looms, detractors are challenging the value of adding drug prices to pharma TV ads.

It's no secret that drug prices are higher in the U.S. than in other countries, and now the Trump administration appears poised to act.

Here's what to watch, now that the Trump administration has set in motion new rules that would require list prices in drug advertising.

After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.

The Senate voted in favor of drug pricing in DTC ads, while HHS works on a transparency proposal for Medicare and Medicaid.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.